The mouse thymoma cell line Bw5417 (short designation within this work Bw) and Jurkat E6.1 (JE6.1), were cultured as described (45 (
link)). Triple parameter reporter cell lines (TPR) and the monoreporter cell line are based on the JE6.1 Jurkat cell line, stably expressing NFκB::eCFP, NFAT::eGFP, and AP-1::mCherry reporter constructs or NFκB::eGFP, respectively as described (46 (
link)).
T cell stimulator cells (TCS) used in this study are Bw5147 cells that stably express membrane-bound single chain antibody fragments derived from the CD3 antibodies (mb-α-CD3) UCHT1 or OKT3 on their surface (47 (
link), 48 (
link)).
A CD14 mAb antibody was used to stain the surface expression of aCD3scFv which were expressed on the cell surface via a c-terminal CD14 sequence (49 (
link)). To exclude the TCS in the reporter assays, an mCD45 antibody was used.
The following flow cytometry antibodies were used in this study: PE-Isotype control (MPOC-21), PE-41BBL (5F4), PE-CD70 (113–16), PE-OX40L (11C3.1), PE-41BB (CD137, 4B4-1), PE-CD27(M-T271), PE-GITR (621), PE-OX40 (CD134, ACT35), APC-CD16 (3G8), APC-CD32 (FUN2), APC-CD64 (10.1), APC-mCD45 (104), APC-CD14 (63D3), PE-CD14 (63D3), FITC-CD56 (HCD56), BV421-CD19 (HIB19), BV421-CD4 (OKT4), PerCP-CD8 (HIT8a, all from Biolegend, San Diego, CA, USA), and PE-GITRL (REA841, Miltenyi Biotec).
For CFSE proliferation assays a functional grade CD3 mAb (UCHT1, Biolegend) was used. For annexin V assays, an FcR silenced CD3 mAb (REA613, Miltenyi Biotec) was used. Agonistic 41BB antibodies - Urelumab (BMS-663513), Utomilumab (PF-05082566), and the CD27 agonist mAb Varlilumab (CDX-1127) were purchased from Creative Biolabs (NY, USA).
For blocking of Fc receptors, cells were incubated for 20 minutes at 4°C with 20 mg/ml Beriglobin (CSL Behring). Flow cytometry analysis was performed using FACSCalibur™ or LSRFortessa™ flow cytometers (BD Bioscience, Franklin Lakes, NJ). FlowJo software (version 10.4.1. Tree Star, Ashland, OR) was used for flow cytometry data analysis.
Leitner J., Egerer R., Waidhofer-Söllner P., Grabmeier-Pfistershammer K, & Steinberger P. (2023). FcγR requirements and costimulatory capacity of Urelumab, Utomilumab, and Varlilumab. Frontiers in Immunology, 14, 1208631.